SCHEMBL3553175

SCHEMBL3553175

CN1CCN(c2cc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c(F)cc2F)CC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCH P24723 17/20 0.64
PRKCD Q05655 17/20 0.64
PRKCQ Q04759 16/20 0.64
PRKCA P17252 16/20 0.64
PRKCE Q02156 15/20 0.64
PRKCB P05771 15/20 0.64
JAK3 P52333 3/20 0.59
PRKCG P05129 3/20 0.59
PRKCZ Q05513 3/20 0.59
CAMK2D Q13557 3/20 0.59
CDK2 P24941 3/20 0.59
PRKD3 O94806 2/20 0.59
ABL1 P00519 2/20 0.59
CDK1 P06493 2/20 0.59
PIM1 P11309 2/20 0.59
PRKCI P41743 2/20 0.59
CAMK2B Q13554 2/20 0.59
CAMK2G Q13555 2/20 0.59
CAMK2A Q9UQM7 2/20 0.59
JAK1 P23458 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4359102 0.91 PRKCH (0.61) PRKCHPRKCDPRKCQPRKCAPRKCE
SCHEMBL3546174 0.85 PRKCA (0.73) PRKCHPRKCDPRKCQPRKCAPRKCE
SCHEMBL3552786 0.81 CCNE2 (0.60) PRKCHPRKCDPRKCQPRKCAPRKCE
SCHEMBL22410995 0.78 PRKCH (1.00) PRKCHPRKCDPRKCQPRKCAPRKCE
SCHEMBL3549510 0.77 PRKCA (0.73) PRKCHPRKCDPRKCQPRKCAPRKCE
SCHEMBL5091472 0.77 PRKCH (0.60) PRKCHPRKCDPRKCQPRKCAPRKCE
SCHEMBL21583796 0.77 JAK3 (0.81) PRKCHPRKCDPRKCQPRKCAPRKCE
SCHEMBL4370794 0.77 GSK3B (0.51) PRKCHPRKCDPRKCQPRKCAPRKCE
SCHEMBL4360100 0.77 PRKCA (0.57) PRKCHPRKCDPRKCQPRKCAPRKCE
SCHEMBL4377883 0.76 PRKCH (1.00) PRKCHPRKCDPRKCQPRKCAPRKCE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1747216-B1 SUBSTITUTED PYRROLE-2, 5-DIONES AS PROTEIN KINASE C INHIBITORS NOVARTIS AG (CH) 2014-01-08 EP claimed
US-7851475-B2 Substituted pyrrole-2, 5-diones as protein kinase C inhibitors NOVARTIS AG (CH) 2010-12-14 US claimed
US-20090221605-A1 SUBSTITUTED PYRROLE-2, 5-DIONES AS PROTEIN KINASE C INHIBITORS NOVARTIS AG (CH) 2009-09-03 US claimed
EP-1747216-A1 SUBSTITUTED PYRROLE-2, 5-DIONES AS PROTEIN KINASE C INHIBITORS Novartis Pharma AG. (CH) 2007-01-31 EP claimed
WO-2005113545-A1 SUBSTITUTED PYRROLE-2, 5-DIONES AS PROTEIN KINASE C INHIBITORS NOVARTIS AG (CH) 2005-12-01 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221605-A1 SUBSTITUTED PYRROLE-2, 5-DIONES AS PROTEIN KINASE C INHIBITORS PRKCA, PRKCB, PRKCE PRKCH 5/4885PRKCD 21/4885PRKCQ 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.